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AbsTrACT
Fatigue is one of the most common symptoms in 
multiple sclerosis (MS), with a major impact on patients’ 
quality of life. Currently, treatment proceeds by trial 
and error with limited success, probably due to the 
presence of multiple different underlying mechanisms. 
Recent neuroscientific advances offer the potential to 
develop tools for differentiating these mechanisms in 
individual patients and ultimately provide a principled 
basis for treatment selection. However, development 
of these tools for differential diagnosis will require 
guidance by pathophysiological and cognitive theories 
that propose mechanisms which can be assessed in 
individual patients. This article provides an overview of 
contemporary pathophysiological theories of fatigue in 
MS and discusses how the mechanisms they propose 
may become measurable with emerging technologies 
and thus lay a foundation for future personalised 
treatments.
InTroduCTIon
Multiple sclerosis (MS) is the most common neuro-
logical disease that causes disability in young adults 
(for recent reviews, see1–3). With an estimated prev-
alence of up to 83%, fatigue is one of the most 
common symptoms in MS4–6 and exerts the greatest 
impact on patients’ quality of life.4 7 Fatigue there-
fore represents one of the most pressing clinical 
problems in the management of MS. Beyond MS, 
fatigue represents a relevant symptom in numerous 
disorders from internal medicine, neurology and 
psychiatry.7–9 In general practice, 20% of patients 
complain of fatigue; this increases up to 50% in 
diseases involving the dysregulation of the immune 
system such as chronic infections, cancer or auto-
immune diseases.10 It is also a frequently reported 
feature of psychiatric diseases and represents a core 
diagnostic criterion of depression in DSM-5.
As for other neuropsychiatric symptoms, fatigue 
likely results from different underlying causes.7 10 At 
present, diagnostic tools are missing which differ-
entiate, in individual patients, between alternative 
potential causes of fatigue. As a consequence, we 
lack a principled basis for treatment selection: while 
several pharmacological and physical therapies are 
used in practice—for example, drugs like amanta-
dine11 or modafinil12 that affect glutamatergic and 
dopaminergic transmission and reuptake of mono-
aminergic transmitters, respectively—treatment 
selection proceeds by trial and error and under 
consideration of side effects, rather than by assess-
ment of individual pathophysiological mechanisms. 
The current absence of objective clinical tests for 
differentiating alternative disease mechanisms 
constitutes a critical barrier to improving individual 
treatment decisions.
Developing tools for differential diagnosis of 
fatigue in MS requires pathophysiological theories 
that propose mechanisms which can, in principle, 
be assessed in individual patients. Previous review 
articles (eg,10) have mostly treated fatigue as a clin-
ical symptom across disorders. In this paper, we 
concentrate on MS and discuss possible pathophys-
iological mechanisms. Our review article provides 
an overview of contemporary theories of fatigue in 
MS and discusses how the mechanisms they propose 
may become measurable with emerging technolo-
gies, potentially leading to differential diagnosis 
and treatment predictions in the future.
Initially, we briefly revisit the definition of fatigue 
and standard diagnostic procedures. This serves 
as a reminder that ‘fatigue’ is not a well-defined 
concept. This is not a trivial issue: one reason for 
the heterogeneity of the literature on fatigue is 
that past studies have assessed different constructs 
of fatigue, for example, not always distinguishing 
between the subjective perception of fatigue and 
externally observable fatigability of cognitive or 
motor functions.
Heterogeneous concepts of ‘fatigue’
Concepts of fatigue vary remarkably in the liter-
ature. For example, fatigue has been described as 
‘a feeling arising from difficulty in initiation of or 
sustaining voluntary effort’,8 ‘an overwhelming 
sense of tiredness that is out of proportion (in rela-
tion to the performed activity)’13 or as a ‘feeling that 
relates to the lack of motivation to deploy resources 
and engage in high effort performance to cope with 
their situation’.10
In an attempt towards standardisation, a recent 
taxonomy distinguishes two major dimensions of 
fatigue: perception of fatigue and performance 
fatigability.5 The latter refers to objectively measur-
able aspects of fatigue, for example, the observ-
able decrease in performance during a cognitive 
or motor task. By contrast, the perceptual dimen-
sion is inherently subjective and cannot be assessed 
directly by an external observer. From a patho-
mechanistic perspective, these two dimensions 
are distinct: explanations of fatigability can, in 
 o
n
 2 April 2019 by guest. Protected by copyright.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2018-320050 on 25 January 2019. Downloaded from 
2 Manjaly Z-M, et al. J Neurol Neurosurg Psychiatry 2019;0:1–10. doi:10.1136/jnnp-2018-320050
Multiple sclerosis
Figure 1 Pathophysiological mechanisms of fatigue discussed in this article. white and grey boxes represent classes of mechanisms and specific 
mechanisms, respectively; directed arrows and circle-ended arrows represent direct and mediating effects, respectively. Due to space limitations, only one 
mechanism per arrow is shown; see main text for other mechanisms. CNS, central nervous system; DA, dopamine; GM, grey matter; NAwM, normally 
appearing white matter; wM, white matter.
principle, be derived from physiological and biochemical prin-
ciples. By contrast, understanding the subjective perception of 
fatigue requires a cognitive perspective, in particular, concepts 
of interoception and metacognition.14–16
For clinical practice, operationalised definitions of fatigue are 
provided by various fatigue questionnaires; see7 17 for overview. 
Some questionnaires were specifically designed for MS.18 Again, 
these questionnaires show notable differences in how they 
operationalise fatigue, which represents an important source of 
heterogeneity in pathophysiological studies of fatigue.17
Pathophysiological concepts of fatigue
This article focuses on four main classes of potential pathophys-
iological mechanisms of fatigue in MS (figure 1):
1. Structural damage of white matter (WM) and grey matter 
(GM),
2. Inflammatory processes (within or outside the central nerv-
ous system, CNS),
3. Maladaptive network recruitment due to distributed lesions 
or inflammation,
4. Metacognition (self-monitoring) of interoception of dysho-
meostatic states.
structural brain damage
MS is characterised by lesions in the CNS that are disseminated 
in space (eg, in the cerebrum, brainstem, spinal cord) and time 
(dynamic changes in lesion load). A key pathological feature of 
MS are WM lesions with demyelination and inflammation that 
lead to axonal damage and progressive degeneration.1 Addition-
ally, GM lesions are present, resulting from cortical demyelination 
due to subpial inflammation, retrograde neuronal degeneration 
following axonal transection and degenerative mechanisms due 
to oxidative injury.19 Beyond demarcated lesions, the above 
processes induce diffuse damage of WM and GM that may lead 
to regional and whole-brain atrophy. Morphometric studies 
reported mixed results on the potential link between global 
measures of brain atrophy and fatigue20–22 and between local 
measures of WM/GM atrophy and fatigue,23–27 respectively. In 
the following, we discuss how different forms of WM and GM 
damage may play a role for the experience of fatigue.
WM lesions
A general idea is that fatigue may result from global impairment of 
brain function due to distributed WM lesions.28 29 Several studies 
have used structural MRI and morphometric analyses of WM 
lesion load to test this idea. Across studies, the overall results are 
mixed: while some studies found a correlation between fatigue 
and global structural damage of WM,20 21 23 30 other studies 
failed to do so.31–34 This inconsistency may partially result from 
differences in methodology, for example, quantifying structural 
brain damage with different morphometric methods.35 An alter-
native explanation for variability across studies is that individual 
degrees of fatigue may be determined more by the locations of 
WM lesions than by global lesion load.24 36 Individual differences 
in normal-appearing white matter might additionally contribute 
to this variability.24 29 As a final factor of variability, there is an 
ongoing debate whether individual disease trajectories of MS 
may be driven differentially by inflammation and neurodegen-
eration37 38; such differences in disease mechanisms could also 
relate to differences in fatigue.
Assuming a correlation between WM damage and fatigue can 
be ascertained, what exactly mediates this link? One explanation 
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concerns fatigability (cognitive or motor): this might originate 
from reduced activation of the central or peripheral targets of 
synaptic connexions due to diminished speed and reliability of 
axonal transmission. In particular, demyelination is known to 
result in the slowing of conduction speed.39 40 Additionally, activ-
ity-dependent conduction block may contribute to fatigability.41 
Therapeutically, fampridine (4-aminopyridine) is thought to 
improve the conduction of action potentials in demyelinated 
nerves by blocking voltage-gated potassium channels.42 Clinical 
studies on the efficacy of fampridine for treating fatigue in MS 
have obtained mixed results so far.43 44
A second explanation refers to structural disconnection, specif-
ically disruption of communication between brain regions with 
functions of relevance for fatigue, such as motor planning and 
execution.45 46 Diffusion-weighted imaging studies demonstrated 
that WM changes are correlated with fatigue, particularly in the 
anterior internal capsule and anterior thalamic tract.23 24 28 29 47 48 
Alternatively, WM damage could disconnect areas of impor-
tance for arousal and motivation.46 This is less well investigated, 
but a tractography study reported altered connectivity between 
posterior hypothalamus and mesencephalon,49 a tract thought 
to contain wakefulness-promoting ascending monoaminergic 
connexions.
GM lesions
GM lesions were long hypothesised to be part of the disease.50 51 
However, it was not until the beginning of the 21st century 
that improved immunohistochemical techniques, high-resolu-
tion structural MRI and quantitative morphometry techniques 
provided clear evidence for GM lesions in MS. GM lesions in 
MS are discussed by several recent reviews.52–54
The spatial distribution of GM lesions in MS is diffuse.55 
Recent neuropathological probability maps of lesions in both 
WM and GM19 emphasised the occurrence of GM lesions in 
regions with deep invaginations, such as insular and anterior 
cingulate cortex (ACC); notably, these are areas of central rele-
vance for interoception, a topic discussed below. Furthermore, 
this study suggested two different degenerative mechanisms 
in cortex, that is, inflammation-induced oxidative injury of 
neurons and retrograde neurodegeneration due to axonal tran-
section.19 In subcortical regions, frequent sites of GM lesions 
include the thalamus, basal ganglia, amygdala, substantia nigra 
and hypothalamus.56
How might GM lesions cause fatigue? First, similarly to WM 
lesions, GM lesions could disturb coordinated activity and 
connectivity in large-scale networks that mediate motor and 
cognitive processes, leading to compensatory activity in addi-
tional nodes and reducing the scope of adaptive changes.57 This 
change in network function might be detected by metacognitive 
mechanisms (see below and figure 1). Empirical investigations of 
cerebral networks in fatigue patients by neuroimaging demon-
strated altered functional connectivity of the basal ganglia,58 
among sensorimotor regions,59 or of the default mode network.60
Second, some of the commonly found deep GM lesions 
affect structures that are directly involved in vigilance, arousal 
and motivation. One prominent example is the hypothalamus, 
which neuropathological studies identified as a frequent lesion 
site in MS61–64 and which is critical for homeostatic regulation 
(see below). Moreover, the lateral hypothalamus hosts neurons 
producing orexin, a neuropeptide of fundamental importance 
for arousal and vigilance. In narcolepsy, a disease with dramat-
ically reduced vigilance, autoimmunological reactions against 
orexin-producing neurons strongly decrease orexin levels.65 
This led to the hypothesis that less pronounced reductions of 
orexin might produce fatigue in MS. For example, hypothalamic 
lesions in MS could lead to partial depletion of orexin; alterna-
tively, immunological processes could affect the synthesis and/or 
postsynaptic efficacy of orexin. So far, studies correlating orexin 
levels in the cerebrospinal fluid (CSF) and fatigue scores have 
provided conflicting results.66 67
A third possibility of how GM lesions may cause fatigue refers 
to the frequent involvement of the brainstem in MS. Specifically, 
lesions of dopaminergic, serotonergic or noradrenergic nuclei in 
the brainstem and the consequent reduction of monoaminergic 
transmitter supply to cortex and basal ganglia could explain the 
reduction in motivation, mood and arousal that characterise 
fatigue.
Finally, GM lesions in hypothalamus or brainstem nuclei 
could disturb the hypothalamus–pituitary–adrenal axis and 
descending neural control of the autonomic nervous system 
leading to persistent endocrine and autonomic disturbances, 
respectively.62 68 This could cause fatigue directly, for example, 
due to diminished energy supply or hypotension; additionally, 
perception of prolonged dyshomeostasis has been postulated to 
underlie subjective experience of fatigue by metacognitive theo-
ries that are described below.14 16
Immunological and inflammatory processes
The immune system plays a key role in aetiology and progression 
of MS.2 3 69 In general, immunological processes in the CNS and 
the body can interact through multiple pathways.70 71 In MS, 
the relative contributions of central and peripheral immunolog-
ical events during the induction and early inflammatory phase 
of MS are not fully understood. In particular, it remains to be 
clarified whether a primary immunological process takes place 
in the brain and spreads to the periphery or whether immune 
activation begins peripherally before being transferred to the 
initially unaffected CNS (for review, see69). The latter possibility 
is supported by the fact that highly effective immunomodula-
tory treatments for MS (eg, fingolimod, rituximab) have periph-
eral targets. Regardless of where the initial immune response 
occurred, myelin damage in the CNS is thought to lead to 
the release of antigens to the periphery.2 This, in turn, primes 
immune responses in lymphoid tissue and triggers the inva-
sion of lymphocytes into the CNS.2 While peripheral immune 
responses may be the driving force at the early stage of MS, 
evidence suggests that later in the disease, the immune response 
is shifted and compartmentalised to the CNS in lymphoid-like 
follicles in the meninges that maintain chronic inflammation.72
Peripheral immunological and inflammatory processes are 
likely to play a central role for fatigue, in general,10 and in 
the specific context of MS.73 74 This is illustrated by ‘sickness 
behaviour’, a syndrome of fatigue, social withdrawal and lowered 
mood during common infections that trigger the production 
of proinflammatory cytokines.75 Furthermore, fatigue can be 
induced by immunomodulatory drugs like interferon-α76 77 or 
vaccinations that trigger production of proinflammatory cyto-
kines.78 These findings raise the question of how peripheral 
immunological and inflammatory processes could affect the 
CNS in MS and impact the experience of fatigue. Several direct 
and indirect immune-to-brain pathways have been unearthed in 
the past few decades, including humoral, cellular and neuronal 
interfaces.10 70 71
Humoral links are established via circumventricular organs 
where inflammatory cytokines can cross the blood–brain barrier 
and bind to neurons with specific receptors; furthermore, 
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cytokines such as IL-6 can exert direct actions on brain endothe-
lial cells to produce inflammatory factors such as prostaglandin 
E2. These processes can trigger both central (eg, microglia acti-
vation, projections to the hypothalamus and nucleus of the soli-
tary tract, NTS) and peripheral (eg, fever) processes. Peripheral 
immune states can also be signalled to the brain by trafficking 
of immune cells, such as monocytes; this constitutes a cellular 
pathway. Finally, neural immune-to-brain pathways consist of 
visceral (especially vagal) afferents that are activated by proin-
flammatory mediators such as interleukin-1.79 Anatomically, 
afferent vagal projections are relayed via the NTS and ventrome-
dial posterior thalamus to posterior and mid-insula.80 81 Insular 
responses to peripheral inflammatory processes have been docu-
mented in humans, for example, using functional neuroimaging 
after induction of acute inflammation by typhoid vaccination80 82 
or after injection of endotoxins.83 This interoceptive pathway is 
an important immune-to-brain link in sickness behaviour and 
plays a central role in metacognitive hypotheses of fatigue (see 
below). It also represents the afferent part of a reflex arc that 
regulates, through NTS projections to the vagal dorsal motor 
nucleus and nucleus ambiguus, peripheral immunological 
processes via hypothalamus–pituitary axis activation and anti-in-
flammatory cholinergic pathways.84
Additionally, several indirect pathways exist how peripheral 
inflammation can affect the CNS. One notable upstream conse-
quence of peripheral inflammation is a reduction in synthesis 
of monoaminergic neurotransmitters such as dopamine, norepi-
nephrine and serotonin.10 71 In brief, peripheral inflammation 
leads to a deficit of tetrahydrobiopterin, an essential cofactor of 
aromatic amino acid hydroxylase enzymes which are critical for 
the synthesis of monoamines. This is a potentially highly rele-
vant mechanism for fatigue: given the well-documented involve-
ment of these neuromodulatory transmitters in motivation 
(dopamine), arousal (norepinephrine) and mood (serotonin), it 
is conceivable that a general reduction in their synthesis could 
produce the clinical picture of fatigue. This idea has been inves-
tigated experimentally in relation to dopamine. For example, 
decreased activity of the dopaminergic midbrain was recently 
demonstrated using functional MRI (fMRI) following typhoid 
vaccination as a model of systemic inflammation.80 85 Similarly, 
18F-dopa PET in patients undergoing therapy with interferon-α 
showed significant changes in presynaptic striatal dopamine 
function, consistent with a decrease in synthesis of dopamine.77
A further indirect mechanism of how peripheral inflammation 
affects the CNS is provided by the kynurenine pathway. This 
pathway is involved in the metabolism of tryptophan, an essen-
tial precursor for monoamine synthesis. In brief, inflammatory 
mediators activate indoleamine-2,3-dioxygenase which degrades 
tryptophan along the kynurenine pathway and thus limits mono-
amine synthesis. Inside the CNS, kynurenine is further metab-
olised to neurotoxic metabolites such as quinolinic acid, an 
NMDA receptor agonist which may trigger excitotoxicity and 
cerebral inflammation.86 Kynurenine has been studied in animal 
models of relapsing–remitting MS, such as experimental autoim-
mune encephalomyelitis, as well as in MS in humans (see87 for 
a review of empirical evidence for altered kynurenine pathway 
activity in MS). While the exact contribution of kynurenines to 
fatigue remains to be established, a recent study in mice demon-
strated that physical exercise activates molecular pathways in 
muscle that accelerate conversion of kynurenine (which can pass 
the blood–brain barrier) into kynurenic acid (which cannot), and 
that this mechanism protects against depressinogenic effects of 
both direct kynurenine administration and chronic stress.88 In 
humans, the volume of the striatum, which is of relevance for 
reward and motivational processes, is inversely associated with 
activation of the kynurenine pathway.89
Following this brief overview of how peripheral inflammation 
may relate to the experience of fatigue, the question remains 
how inflammation inside the CNS might lead to fatigue. One 
possibility relates to dopamine: CNS inflammation triggers acti-
vation of microglia, and the ensuing production of cytokines in 
situ negatively affects dopaminergic transmission, for example, 
through direct effects on dopamine transporters and receptor 
function (for review, see10). This has motivated a view of fatigue 
as resulting from altered connectivity between striatum and 
prefrontal cortex.8 90 The efficacy of this connexion depends on 
dopaminergic meso-prefrontal afferents and has been implicated 
in reward-oriented learning and motivation.91 In brief, from this 
view, fatigue is conceptualised as a variation of altered response 
to reward and the ensuing decrease in motivation.
An alternative mechanism for how inflammation within the 
CNS could produce fatigue rests on orexin, a neuropeptide 
produced by neurons in the lateral hypothalamus.65 In addition 
to its critical role for vigilance and arousal (as visible in narco-
lepsy, see above), orexin is involved in the sleep–wake cycle, 
reward processing and food intake. Animal studies found that 
inflammation-induced lethargy is mediated by suppression of 
orexin neuron activity by interleukin-1β and TNF-α92 and that 
orexin levels correlate with diminished vigilance and explor-
atory behaviour.93 Concerning MS, the role of orexin for fatigue 
has not yet been firmly established: studies on the correlation 
between fatigue and CSF orexin levels have provided contradic-
tory results.66 67
Maladaptive network recruitment during task performance
Functional imaging studies have demonstrated that patients 
with MS affected by fatigue, compared with patients with 
MS without fatigue and healthy controls, frequently show an 
increase of distributed brain activity during the performance 
of tasks.45 47 94 95 In the spinal cord, patients with MS with 
fatigue, despite smaller WM lesion load, show higher functional 
recruitment of the cervical cord than patients with MS without 
fatigue96 (for discussion, see97). Moreover, patients with MS 
with fatigue often fail to show physiological adaptation of brain 
activity during tasks57 (but see98). This may differ across disease 
stages and brain regions.99 100
One possible explanation for altered cortical activity in MS 
is that networks mediating specific cognitive operations are 
perturbed by one of the mechanisms described above, that is, 
WM/GM lesions or functional impairments due to inflamma-
tory processes. In order to maintain cognitive performance 
despite lesion-induced or inflammation-induced loss of network 
function, compensatory recruitment of neuronal tissue may 
be needed, either in terms of additional regions not usually 
contributing to a particular task and/or in terms of unusually 
high levels of activation. Analogous findings have been obtained 
in other diseases with discrete lesions, such as stroke.101 What-
ever the cause of altered cortical activity, the question remains 
how aberrant activity levels are linked to subjective experience 
of fatigue. One possibility is that the activation of ‘atypical’ and 
the compensatory (non-adapting) activation of ‘typical’ regions 
might be detected by self-monitoring mechanisms, a metacogni-
tive perspective we discuss below.
An alternative possibility is that impairment of neuromodula-
tory projections from the brainstem—by lesions or by inflamma-
tion-induced decrease of transmitter synthesis102—could lead to 
a functional reorganisation of cortical networks. This is because 
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Figure 2 A coarse schematic overview of the inference–control–
metacognition loop for bodily regulation (for details, see16). interoceptive 
surprise as a possible computational substrate of fatigue can arise from 
perturbations of any components of this loop: (1) actual perturbations 
of bodily state that evade cerebral attempts of correction (eg, chronic 
inflammation, cancer); (2) altered interosensations (due to pathologies 
of interoceptors or afferent pathways); (3) disturbances of interoception 
(eg, inflammatory lesions of insula); (4) disturbances of interoactions 
(neuronally or endocrinologically mediated cerebral influences on 
bodily functions), for example, inflammatory lesions of ACC, brainstem, 
hypothalamus or their projections; (5) altered metacognitive processes (eg, 
changes in expected performance levels). The multiple failure loci offer a 
potential explanation for the clinical heterogeneity of fatigue and speaks 
to the necessity of developing tools for differential diagnostics at the circuit 
level.
neuromodulatory transmitters profoundly influence activity and 
connectivity in cortex, by two major mechanisms. First, they 
regulate neuronal gain and excitability via slow afterhyperpo-
larisation currents mediated by calcium-dependent potassium 
channels103; second, they alter both short-term and long-term 
synaptic plasticity by modulating NMDA receptors.104 Rapid 
functional reorganisation of cortical networks in response to 
manipulations of neuromodulatory transmitters was demon-
strated in human and animal studies,105 106 and it is conceivable 
that similar effects could arise from brainstem lesions in MS or 
through effects of inflammation on monoamine synthesis.102
Metacognitive perspective on fatigue
The disease theories discussed so far offer potential physiological 
mechanisms but do not explain how the subjective experience 
of fatigue might arise. A metacognitive perspective may provide 
a crucial bridge here. Metacognition corresponds to cognition 
about cognition, such as judging the accuracy of a perceptual 
decision.107 In cybernetic theories of brain function, metacogni-
tion is understood as ‘self-monitoring of one’s level of mastery 
in acting on the world… and can be seen as a high-level form of 
inference about one’s capacity for control’16 (figure 2). Three 
metacognitive mechanisms of fatigue have been proposed—with 
emphasis on (1) interoception, that is, the perception of bodily 
states, (2) network-level function and (3) perceived effort of 
movements, respectively.
First, interoception—the perception of the physiological state 
of the body, including blood oxygenation, acidity and osmo-
lality; heart rate; plasma concentration of glucose, hormones, 
cytokines and so on—is disturbed in MS108 and is increas-
ingly recognised as an important factor for the experience of 
fatigue.70 109 The interoception-related metacognitive theory 
views fatigue as resulting from the brain’s inference about its 
capacity for control.14 Specifically, it postulates that fatigue 
reflects the metacognitive diagnosis that the brain is failing to 
exert control over bodily states and does not have any action 
at its disposal to overcome a state of dyshomeostasis. Given 
this inferred helplessness or low ‘allostatic self-efficacy’, fatigue 
would correspond to a feeling state that signals the futility of any 
further actions. A central notion of this theory is that the brain’s 
capacity to regulate bodily states is represented by a compact 
information-theoretic quantity (ie, interoceptive surprise) that 
can be accessed by metacognitive areas. Neuronally, interocep-
tive surprise can be computed from prediction error signals that 
index the mismatch between expected and actual bodily states 
(figure 3). These prediction errors are thought to be signalled 
by pyramidal cells in supragranular layers of interoceptive areas 
(eg, insula, ACC) and to require ionotropic glutamatergic recep-
tors, particularly NMDA receptors.14 110 111 While this exact 
mechanism remains to be demonstrated experimentally, the 
general theory is supported by empirical evidence from different 
investigations, including the correlation of activity in insula and 
ACC with subjectively perceived fatigue during experimentally 
controlled states of dyshomeostasis, such as induced inflamma-
tion.80 82 Moreover, the theory explains why fatigue is a frequent 
symptom of any disease that involves chronic dyshomeostatic 
states, including immunological, metabolic, endocrine, cardio-
vascular, hepatic and renal diseases.9 10 Notably, recent neuro-
imaging investigations of patients with MS demonstrated that 
electrophysiological markers of interoception are altered; at 
the same time, insula and ACC were found to show structural 
atrophy and abnormal functional connectivity.108
A clinically important corollary of this theory is that fatigue 
necessarily has very different causes. This is because interocep-
tive surprise can arise from disturbances of any component of 
the closed-loop relation between interoception, bodily regula-
tion and metacognition16 (see figure 2). Notably, interoceptive 
surprise can result from merely perceived dyshomeostasis. This 
could occur when the cortical areas that infer bodily states are 
perturbed, for example, due to inflammatory lesions of the 
insula which are frequent in MS.19 The ensuing ‘illusion’ of 
dyshomeostasis would elicit misinformed interoactions, creating 
dyshomeostatic bodily states that reify the initially spurious 
interoceptive surprise and render it chronic. Similarly, primary 
disturbances of interoactions—for example, due to inflamma-
tory lesions of visceromotor areas like ACC,19 hypothalamus62 
or brainstem nuclei—would produce lasting perturbations of 
bodily states.
Second, fatigue might also arise from other forms of prediction 
error or surprise that the brain finds itself unable to reduce.14 109 
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Figure 3 Neuroanatomically specific circuit model of interoception that plays a central role in theories of fatigue from computational psychiatry.14 The 
regions are based on anatomical investigations of interoeptive circuitry81; the network they form is thought to instantiate a predictive model of bodily 
states.111 in this hierarchical network, predictions are sent from higher to lower areas, while prediction errors (Pes; the difference between actual and 
predicted states) are signalled in the opposite direction and used to update predictions (‘predictive coding’110). Specifically, hierarchically higher visceromotor 
areas, such as the anterior insula (Ai) and anterior cingulate cortex (ACC), are thought to tune homeostatic reflex arcs by means of allostatic predictions 
computed from bodily and environmental information. in turn, Ai/ACC inform hierarchically lower areas, such as posterior and mid-insula, about the 
expected interosensory consequences (corollary discharge). The latter areas compare these predictions against actual interosensory input and return Pe that 
serve to update the predictions by Ai/ACC. At the top of the hierarchy, metacognitive areas (possibly medial prefrontal cortex, mPFC) monitor the level of 
Pe and compute interoceptive surprise. The better the predicted bodily states can be achieved through regulatory action, the smaller Pe and interoceptive 
surprise. importantly, because of the closed-loop nature of brain–body interactions (figure 2), impairments of any part of the network can lead to chronic 
interoceptive surprise. This may lead to the metacognitive diagnosis of helplessness or low allostatic self-efficacy (lack of control over bodily states) and has 
been posited as the substrate for fatigue as a feeling state.14
The brain’s self-monitoring of performance is not restricted to 
interoception and its associated circuitry; instead, expectations 
are held about any domain of cognition, and domain-indepen-
dent mechanisms of metacognition exist112 which might ‘read 
out’ error signals from domain-specific functional networks.16 
In MS, lesions outside interoceptive pathways impair perfor-
mance levels of many cognitive and motor acts, as reflected by 
progressive changes in functional networks.113 Similar to fatigue 
resulting from bodily dyshomeostasis, this might lead to fatigue 
as a metacognitive diagnosis of network function: the brain’s 
interpretation of its own state as a chronic mismatch between 
actual and expected performance levels that is not amenable to 
actions.14
Finally, a third proposed metacognitive mechanism of fatigue 
focuses exclusively on the sensorimotor system.15 This concept 
assumes that diminished sensory attenuation during the execu-
tion of movements would lead to proprioceptive prediction 
errors, requiring the brain to conclude that movements require 
more effort than predicted. Thus, here the emphasis is on fatigue 
as a direct consequence of unexpectedly high perceived effort 
during movements (proprioceptive surprise) as a cognitive cause 
of fatigue.
Towards differential diagnosis and targeted treatment of 
fatigue
Treatment of fatigue in MS involves the initial exclusion of 
MS-unrelated causes, for example, anaemia, hypothyroidism 
or sleep disturbances such as obstructive sleep apnoea. Subse-
quently, the choice of disease-modifying drugs could be oriented 
towards drugs with potentially beneficial effects on fatigue. For 
example, glatiramer acetate might reduce fatigue more effec-
tively than β-interferon.114 Some studies demonstrated that 
natalizumab may decrease fatigue in patients with MS,115 116 
although this might result from a primary effect of natalizumab 
on depression.117
A central question for this review is how fatigue-specific treat-
ments could be personalised, given that fatigue in MS likely 
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arises through multiple mechanisms (figure 1). In clinical prac-
tice, we are presently unable to differentiate between alterna-
tive causes of fatigue in individual patients. As a consequence, 
current treatment of fatigue is driven by trial and error and 
consideration of side effects. Treatment strategies for fatigue in 
MS include both pharmacological approaches (eg, the NMDA 
receptor antagonist amantadine, stimulants such as modafinil, or 
antidepressants) and non-pharmacological strategies (eg, mind-
fulness-based cognitive therapy (MBCT), cognitive-behavioural 
therapy or exercise) (for recent reviews, see118 119). Additionally, 
social factors, cognitive profiles and psychological traits modu-
late fatigue120 121; these may offer additional entry points for 
therapeutic interventions.
In order to select treatments in a rational and predictive 
manner, novel clinical tests are needed. Importantly, these need 
to go beyond detecting fatigue; instead, they should inform the 
choice of patient-specific treatment—by enabling differential 
diagnosis of alternative mechanisms and/or predicting indi-
vidual therapeutic response. Some of the candidate mechanisms 
discussed above map onto existing treatment approaches; others 
suggest novel treatment strategies. How could these be identi-
fied, in individual patients, with existing or emerging techniques?
As all of the pathophysiological mechanisms discussed above 
eventually lead to changes in network function, measures of 
brain connectivity are of central importance. In the domain 
of fMRI, methodological developments have enabled a transi-
tion from simple estimates of undirected coupling (functional 
connectivity) to model-based measures of directed influences 
between neuronal populations (effective connectivity). The 
latter have become increasingly sophisticated—with an ability 
to resolve neuronal versus haemodynamic contributions to 
layer-wise fMRI signals and characterising transient modula-
tory influences122—and are increasingly used in translational 
neuroimaging.123 Furthermore, recent developments allow for 
computationally efficient whole-brain estimates of effective 
connectivity,124 which is important for diseases with distributed 
pathology as MS.
In conjunction with high-resolution fMRI, models of effec-
tive connectivity could probe specific candidate mechanisms of 
fatigue in individual patients, with implications for treatment 
choice. For example, occult dysfunction of specific nuclei—
say through inflammation-induced reduction of monoamin-
ergic transmitter synthesis in brainstem nuclei or of orexin in 
lateral hypothalamus—could be inferred by assessing efferent 
connexion strengths of the corresponding nuclei to known 
target regions (or across the whole brain). For assays of mono-
aminergic nuclei, this approach could be further enhanced by 
computational models of transmitter release, respectively.125 If 
abnormal connectivity of specific nuclei can be established (eg, 
in comparison with reference distributions), this may predict 
beneficial therapeutic effects of stimulants (modafinil) or 
selective serotonin reuptake inhibitors/selective norepineph-
rine reuptake inhibitors.
Similarly, estimates of effective connectivity between areas 
involved in interoception, homeostatic control and metacog-
nition could help identify patients in whom fatigue results 
from a metacognitive diagnosis of helplessness with regard to 
overcoming dyshomeostasis (compare figure 3). This could 
be combined with inflammation-sensitive MRI sequences82 
and designed perturbations of interoceptive and homeostatic 
processes16 to detect abnormalities in key circuit components 
frequently affected by inflammation and lesions in MS.19 62 If 
investigations of this sort point to a metacognitive/interocep-
tive origin of fatigue, this may predict therapeutic efficacy of 
MBCT126 or related forms of contemplative training with a 
focus on interoception.
Moving from MRI to electrophysiological techniques, 
several approaches could contribute to differential diagnosis 
and prognosis of fatigue in MS.127 128 For example, multimodal 
(visual, auditory, somatosensory, motor) evoked potentials 
(EPs) measured by electroencephalography (EEG) and transcra-
nial magnetic stimulation (TMS), respectively, have predictive 
value with regard to future disability status in general.129 130 
By contrast, there are hardly any prospective EP studies with 
a specific focus on predicting fatigue. One such study high-
lighting the potential use of EPs suggested that the auditory 
P300 potential may predict treatment response to modafinil, 
although with moderate sensitivity and specificity.131
Recently developed computational methods might enhance 
the use of EEG data for differential diagnosis of fatigue and 
treatment prediction. For example, biophysical models of EEG 
data have shown promising potential for detecting patholo-
gies at the synaptic level, including dysfunction of the NMDA 
receptor.132 Models of this kind might help inform individual 
application of amantadine, one of the few agents featuring 
in official guidelines (National Institute for Health and Care 
Excellence, UK), but with only weak efficacy in non-selected 
patients.118 Similar models of magnetoencephalography data 
from patients with monogenetic channelopathies have demon-
strated that it may be possible to identify selective alterations 
of specific ion channels, such as voltage-gated potassium chan-
nels.133 This approach could help in identifying those fatigue 
patients who might benefit from treatment with fampridine. 
This question might also be addressed by TMS: a prospec-
tive study using motor EPs in patients with MS fatigue prior 
to therapy with fampridine showed that increased central 
motor conduction time might predict individual treatment 
response.134
ConClusIons And ouTlook
Despite its frequency and pronounced impact on the lives 
of patients with MS, techniques for differential diagnosis of 
fatigue and mechanism-guided treatment selection in indi-
vidual patients do not exist. A critical basis for developing 
such methods are pathophysiological theories about the 
mechanisms of fatigue. This paper has reviewed contempo-
rary theories about four major classes of disease mechanisms 
leading to fatigue: structural damage of WM/GM, inflamma-
tory processes, maladaptive network recruitment during task 
performance and metacognitive interpretations of brain states 
that suggest ‘helplessness’. We anticipate that these theories 
together with recent advances in high-resolution functional 
neuroimaging and computational modelling will guide the 
development of tools for differential diagnosis. Similar to 
ongoing efforts in psychiatry,123 computational neuroim-
aging tools may provide indices of different causes of fatigue 
that support treatment decisions in individual patients. This 
represents an exciting and promising endeavour, but will 
require prospective patient studies for validating the clinical 
use of candidate tools.
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